Phase I/II Study of Irinotecan and Gemcitabine in Pediatric, adolescent and Young Adult Patients with Relapsed or Refractory Solid Tumors
Phase 1
- Conditions
- Relapse/refractory pediatric/AYA solid tumor
- Registration Number
- JPRN-UMIN000020144
- Lead Sponsor
- Group for "combination chemotherapies for refractory Adolescent and Young Adult solid tumors "
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment 2. Active infection requiring systemic medication 3. abnormality in electrocardiogram tested within 28 days, requiring intervention 4. respiratory or heart disorder requiring oxygen supply, except from malignant pleural effusion 5. diarrhea >= Grade2 6. Women during pregnancy or breast-feeding 7. Psychosis 8. Systemic steroids or other immunosuppressants medication 9. Principal investigator determines that the case is Inappropriate to register for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method